

FOI 3138

18<sup>th</sup> June 2025

**FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST**

**How many patients were treated in total, regardless of diagnosis, with the following medicines in the**

**3 months between the start of January 2025 and end of March 2025, or latest 3-month period available?**

**Response:**

Name of medicine	Number patients treated
1.1 Fedratinib (Inrebic)	0
1.2 Momelotinib (Omjjara)	2
1.3 Ruxolitinib (Jakavi)	20
1.4 Hydroxycarbamide	172

**How many patients were treated for the following myeloproliferative diseases in the 3 months between the start of January 2025 and end of March 2025, or latest 3-month period available?**

**Response:**

Diagnosis with ICD10 codes	Number patients treated
2.1 Polycythaemia vera ICD10 codes = D45, D450, D45.0, D45X OR morphology code = 9950/3	0
2.2 Myelofibrosis ICD10 codes = C944, C94.4 or D474, D47.4; OR morphology codes = 9931/3 or 9961/3	8
2.3 Essential thrombocythemia ICD10 code = D473, D47.3 OR morphology code = 9962/3	55
2.4 Myeloproliferative Disease, Chronic ICD10 code = D471, D47.1	17

**How many patients with Myelofibrosis (ICD10 codes = C944 or D474; OR morphology codes = 9931/3 or 9961/3) were treated with the following medicines in the 3 months between the start of January 2025 and end of March 2025, or latest 3-month period available?**

**Response:**

This information is not recorded centrally. As such we cannot provide this as the cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this information from a number of individual patient records it would exceed the £450 limit and is therefore cost prohibitive.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

Name of medicine	Number patients treated
3.1 Ruxolitinib (Jakavi)	
3.2 Hydroxycarbamide	

**How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of January 2025 and end of March 2025, or latest 3-month period available?**

**Response:**

Name of medicine	Number patients treated
4.1 Acalabrutinib (Calquence)	28
4.2 Ibrutinib (Imbruvica)	11
4.3 Pirtobrutinib (Jaypirca)	0
4.4 Venetoclax (Venclyxto)	1
4.5 Zanubrutinib (Brukinsa)	4
4.6 Rituximab	Not available
4.7 Obinutuzumab (Gazyvaro)	12

**How many patients with Chronic Lymphocytic Leukaemia OR Small B-Cell Lymphoma – ICD10 codes = C911, C91.1 OR C830, C83.0 - were treated with the following medicines in the 3 months between the start of January 2025 and end of March 2025, or latest 3-month period available?**

**Response:**

This information is not recorded centrally. As such we cannot provide this as the cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this information from a number of individual patient records it would exceed the £450 limit and is therefore cost prohibitive.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

Name of medicine	Number patients treated
5.1 Acalabrutinib (Calquence)	
5.2 Ibrutinib (Imbruvica)	
5.3 Pirtobrutinib (Jaypirca)	
5.4 Venetoclax (Venclyxto)	
5.5 Zanubrutinib (Brukinsa)	
5.6 Obinutuzumab (Gazyvaro)	
5.7 Rituximab	
5.8 Bendamustine	
5.9 Chlorambucil	
5.10 Fludarabine	
5.11 Cyclophosphamide	

**How many patients with Chronic Lymphocytic Leukaemia OR Small B-Cell Lymphoma were treated with the following medicines as monotherapy, or in combination, in the 3 months between the start of January 2025 and end of March 2025, or latest 3-month period available?**

**Response:**

This information is not recorded centrally. As such we cannot provide this as the cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this information from a number of individual patient records it would exceed the £450 limit and is therefore cost prohibitive.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

Name of monotherapy or combination	Number patients treated
6.1 Ibrutinib + venetoclax	
6.2 Obinutuzumab + venetoclax	

<b>6.3 Zanubrutinib monotherapy / maintenance</b>	
<b>6.4 Ibrutinib monotherapy / maintenance</b>	
<b>6.5 Venetoclax monotherapy</b>	
<b>6.6 Venetoclax + rituximab</b>	
<b>6.7 Rituximab monotherapy</b>	

**How many patients with Mantle Cell Lymphoma (ICD-10 code = C83.1) were treated with the following medicines, in the 3 months between the start of January 2025 and end of March 2025, or latest 3-month period available?**

**Response:**

This information is not recorded centrally. As such we cannot provide this as the cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this information from a number of individual patient records it would exceed the £450 limit and is therefore cost prohibitive.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

Name of monotherapy or combination	Number patients treated
7.1 Acalabrutinib	
7.2 Ibrutinib	
7.3 Zanubrutinib	

Email: [Foi.Team@Southerntrust.hscni.net](mailto:Foi.Team@Southerntrust.hscni.net)